文献速递脊柱关节炎

银屑病关节炎TNF抑制剂失败后循环换药与机制转换策略的系统评价与荟萃分析

Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该荟萃分析纳入5项观察性研究共2300例PsA患者,比较TNFi失败后循环使用另一种TNFi与换用不同机制bDMARD的策略。结果显示两组在无应答、12个月和24个月保留率及不良事件方面均无显著差异,提示治疗选择可依据临床特征和患者偏好。

要点

  • TNFi失败后循环与转换策略在无应答、保留率和安全性上无显著差异。
  • 纳入研究均为观察性设计,异质性较高(I²最高达94%)。
  • 治疗选择可基于临床特征和患者偏好,而非总体疗效差异。

核心结论

  • TNFi失败后,循环换用另一种TNFi与换用不同机制bDMARD在保留率和安全性方面相当。
  • 治疗选择可能应依据临床特征和患者偏好,而非总体有效性差异。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase和Cochrane Central。
  • 纳入比较循环与转换策略的随机对照试验和观察性研究。
  • 最终分析5项观察性研究,共2300例PsA患者。

主要发现

  • 1517例(66.0%)接受循环策略,783例(34.0%)接受转换策略。
  • 第二次bDMARD前病程范围为3.7至12年。
  • 无应答风险比RR 0.99(95%CI 0.70-1.41;I²=92%),组间无显著差异。
  • 12个月保留率RR 0.91(95%CI 0.75-1.10;I²=79%),无显著差异。
  • 24个月保留率RR 0.96(95%CI 0.53-1.75;I²=94%),无显著差异;不良事件RR 0.94(95%CI 0.38-2.34;I²=71%),无显著差异。

关键数值与推荐

  • 主要结局包括无应答、12个月保留、24个月保留和不良事件。
  • 采用合并风险比(RR)及95%CI进行汇总分析。
  • 首次TNFi停药的主要原因按各研究定义均为无应答(含原发无应答和继发失效)。

临床怎么用

  • TNFi失败后,循环或转换策略均可作为选择,需结合患者临床特征和偏好个体化决策。
  • 因缺乏显著疗效差异,不应仅基于策略类型优先选择某一方案。

局限性

  • 仅纳入观察性研究,存在选择偏倚和混杂可能。
  • 各结局异质性较高(I²范围71%-94%)。
  • 首次TNFi停药原因的定义在各研究间不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Biologic DMARDs (bDMARDs) are widely used to treat moderate to severe PsA. TNF inhibitors (TNFi) are the most common initial biologic owing to their long market availability, clinician familiarity and lower cost. However, the optimal strategy following TNFi failure, cycling to another TNFi or swapping to a bDMARD with a different mechanism, remains uncertain. This meta-analysis compared the two strategies in these patients. METHODS: PubMed, Embase and Cochrane Central were searched for randomized controlled trials and observational studies comparing cycling with swapping in PsA. Outcomes included: (i) lack of response; (ii) 12-month retention; (iii) 24-month retention; and (iv) adverse events. Pooled risk ratios (RR) with 95% CI were calculated. RESULTS: Five observational studies, including 2300 PsA patients, were analysed; 1517 (66.0%) received cycling and 783 (34.0%) received swapping strategies. Disease duration before the second bDMARD ranged from 3.7 to 12 years. The main cause of discontinuation of the first TNFi before switching was lack of response (including primary non-response and secondary loss of response) according to individual study definitions. No significant differences were observed between groups for lack of response (RR 0.99; 95% CI 0.70-1.41; I2 = 92%), 12-month retention (RR 0.91; 95% CI 0.75-1.10; I2 = 79%), 24-month retention (RR 0.96; 95% CI 0.53-1.75; I2 = 94%) or adverse events (RR 0.94; 95% CI 0.38-2.34; I2 = 71%). CONCLUSION: Following TNFi failure, cycling and swapping strategies show comparable retention and safety, suggesting that treatment choice may be guided by clinical characteristics and patient preference rather than clear differences in overall effectiveness.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tomo ATJ, Ratan P, Gonçalves LS, et al. Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis. Rheumatology (Oxford). 2026. PMID: 42216248. doi:10.1093/rheumatology/keag281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。